Inflammatory mediator reduction

Inflammatory mediator reduction" refers to the therapeutic strategy or pharmacological approach of lowering the levels or activity of multiple substances (such as cytokines, chemokines, prostaglandins, leukotrienes, and other inflammatory molecules) that drive inflammation in diseases. This phrase does not designate a specific molecular entity but rather a category of intervention that can be achieved by targeting a diverse range of molecules and pathways, including cytokines (e.g., TNF-α, IL-1β, IL-6), enzymes (COX, LOX), or transcription factors (NF-κB)[3][4][10]. Because it is a functional/therapeutic description and not the name of a defined molecular target, it is not suitable for direct molecular annotation in target-based drug discovery or structured pharmacological databases.\n\nIf you are interested in the reduction of a specific inflammatory mediator (e.g., "Tumor necrosis factor-alpha" or "Interleukin-6 receptor"), please specify that molecule to receive a structured target entry[3][4].